Our client, a global, top-20 pharmaceutical company developed a new medication to treat multiple myeloma (MM), a progressive hematological cancer considered to be incurable. In the past decade, various new drugs for the treatment of MM were developed and approved. The competitive landscape for this drug is large and will become even larger in the coming years, as further drugs are in the pipeline.
Current treatment options have some drawbacks concerning safety, convenience, and sustainability. The new medication aims at meeting these unmet needs. Several early phase clinical studies of the drug have already had promising outcomes and phase III studies were ongoing. The medication was just approved by the FDA when the client contacted us to discuss strategies and tactics to train new employees. These employees would have to be thoroughly trained to understand the therapeutic area, the product, the competitive landscape, and the underlying studies.